Literature DB >> 20497310

HCV synergizes with body weight in the promotion of insulin resistance.

A Delgado-Borrego1, Y Kamegaya, S H Jordan, S Agrawal, C Valim, R T Chung.   

Abstract

Hepatitis C virus (HCV) infection appears to contribute to the development of insulin resistance (IR). Among the multiple determinants of IR, body mass index (BMI) is the most important. We investigated the contribution of HCV to BMI-associated IR using a transgenic mouse model expressing HCV core protein. Eight transgenic and five nontransgenic littermate controls were evaluated. Glucose and insulin tolerance tests (ITT) were performed on two separate occasions. Multivariate linear mixed modelling was used to evaluate and compare the effect of weight on IR between HCV core transgenic and nontransgenic controls. There were no statistically significant differences in glucose or ITT (P = 0.58 and P = 0.59, respectively) between the two groups, and no difference in median weights between transgenic and control mice (P = 0.11). However, there was greater variance in the distributions of Tg when compared to nontransgenic mice for both glucose and insulin tolerance. When evaluating this closely, a differential contribution of weight to IR curves between these groups was noted (P = 0.05). Among nontransgenic mice, IR curves for mice of different weights were comparable, however, for transgenic mice, higher weights resulted in larger levels of IR curves with slower decay. In all animals, steatosis was absent or minimal. We conclude that weight has a greater effect on IR in HCV core expressing transgenic mice than littermate controls. HCV therefore synergizes with weight in the promotion of IR. Steatosis was not a prerequisite for the development of IR, implying that HCV's effects on IR may be independent of steatosis.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 20497310      PMCID: PMC3806633          DOI: 10.1111/j.1365-2893.2010.01291.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  46 in total

1.  Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited.

Authors:  I Zavaroni; L Bonini; P Gasparini; A L Barilli; A Zuccarelli; E Dall'Aglio; R Delsignore; G M Reaven
Journal:  Metabolism       Date:  1999-08       Impact factor: 8.694

2.  Extrahepatic manifestations of hepatitis C virus infection.

Authors:  J M Durand
Journal:  Am J Gastroenterol       Date:  1997-08       Impact factor: 10.864

3.  Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis.

Authors:  L F Hourigan; G A Macdonald; D Purdie; V H Whitehall; C Shorthouse; A Clouston; E E Powell
Journal:  Hepatology       Date:  1999-04       Impact factor: 17.425

4.  Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection.

Authors:  S Caronia; K Taylor; L Pagliaro; C Carr; U Palazzo; J Petrik; S O'Rahilly; S Shore; B D Tom; G J Alexander
Journal:  Hepatology       Date:  1999-10       Impact factor: 17.425

5.  The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice.

Authors:  K Moriya; H Fujie; Y Shintani; H Yotsuyanagi; T Tsutsumi; K Ishibashi; Y Matsuura; S Kimura; T Miyamura; K Koike
Journal:  Nat Med       Date:  1998-09       Impact factor: 53.440

6.  Higher incidence of diabetes in liver transplant recipients with hepatitis C.

Authors:  H Knobler; A Stagnaro-Green; S Wallenstein; M Schwartz; S H Roman
Journal:  J Clin Gastroenterol       Date:  1998-01       Impact factor: 3.062

7.  Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection.

Authors:  D R Nelson; H L Lim; C G Marousis; J W Fang; G L Davis; L Shen; M S Urdea; J A Kolberg; J Y Lau
Journal:  Dig Dis Sci       Date:  1997-12       Impact factor: 3.199

8.  Diabetes mellitus is associated with chronic hepatitis C but not chronic hepatitis B infection.

Authors:  G M Fraser; I Harman; N Meller; Y Niv; A Porath
Journal:  Isr J Med Sci       Date:  1996-07

9.  Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways.

Authors:  G Svegliati-Baroni; F Ridolfi; A Di Sario; A Casini; L Marucci; G Gaggiotti; P Orlandoni; G Macarri; L Perego; A Benedetti; F Folli
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

10.  Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C.

Authors:  E Larrea; N Garcia; C Qian; M P Civeira; J Prieto
Journal:  Hepatology       Date:  1996-02       Impact factor: 17.425

View more
  2 in total

1.  Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort.

Authors:  Tangui Barré; Fabrice Carrat; Clémence Ramier; Hélène Fontaine; Vincent Di Beo; Morgane Bureau; Céline Dorival; Dominique Larrey; Elisabeth Delarocque-Astagneau; Philippe Mathurin; Fabienne Marcellin; Ventzislava Petrov-Sanchez; Carole Cagnot; Patrizia Carrieri; Stanislas Pol; Camelia Protopopescu
Journal:  J Cannabis Res       Date:  2022-06-11

2.  Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action.

Authors:  Danielle Brandman; Peter Bacchetti; Claudia E Ayala; Jacquelyn J Maher; Mandana Khalili
Journal:  Diabetes Care       Date:  2012-03-07       Impact factor: 19.112

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.